Development of TACE Refractoriness Scores in Hepatocellular Carcinoma

被引:15
作者
Chen, Li [1 ]
Yu, Chen-Xi [1 ]
Zhong, Bin-Yan [2 ]
Zhu, Hai-Dong [1 ]
Jin, Zhi-Cheng [1 ]
Zhu, Guang-Yu [1 ]
Zhang, Qi [1 ]
Ni, Cai-Fang [2 ]
Teng, Gao-Jun [1 ]
机构
[1] Southeast Univ, Med Sch, Ctr Intervent Radiol & Vasc Surg, Dept Radiol,Zhongda Hosp, Nanjing, Peoples R China
[2] Soochow Univ, Dept Intervent Radiol, Affiliated Hosp 1, Suzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatocellular carcinoma; transarterial embolization refractory; risk factors; nomogram; overall survival; TRANSARTERIAL CHEMOEMBOLIZATION; CONSENSUS RECOMMENDATIONS; PROGNOSTIC INDEX; SORAFENIB; EFFICACY; CANCER; GUIDELINES; MANAGEMENT; DIAGNOSIS; STRATEGY;
D O I
10.3389/fmolb.2021.615133
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To identify the independent risk factors for transarterial embolization (TACE) refractoriness and to develop a novel TACE refractoriness score and nomogram for predicting TACE refractoriness in patients with hepatocellular carcinoma (HCC). Methods: Between March 2006 and March 2016, HCC patients who underwent TACE monotherapy as initial treatment at two hospitals formed the study cohort and validation cohort. The criteria of TACE refractoriness followed the Japan Society of Hepatology 2014 version of TACE refractoriness. In the study cohort, the independent risk factors for TACE refractoriness were identified, and TACE refractoriness score and nomogram were then developed. The accuracy of the systems was validated externally in the validation cohort. Results: In total, 113 patients from hospital A formed the study cohort and 122 patients from hospital B formed the validation cohort. In the study cohort, 82.3% of the patients (n = 93) developed TACE refractoriness with a median overall survival (OS) of 540 days (95% CI, 400.8-679.1), and the remaining 20 patients in the TACE-non-refractory group had a median OS of 1,257 days (95% CI, 338.8-2,175.2) (p = 0.019). The median time for developing TACE refractoriness was 207 days (95% CI, 134.8-279.2), and a median number of two TACE procedures were performed after refractoriness developed. The independent risk factors for TACE refractoriness were the number of tumors and bilobular invasion of HCC. TACE refractoriness scores <3.5 indicated a lower incidence of TACE refractoriness, whereas scores >3.5 points indicated a higher incidence (p < 0.001). In the validation cohort, 77.9% of the patients (n = 95) developed TACE refractoriness with a median OS of 568 days (95% CI, 416.3-719.7), and a median OS of 1,324 days was observed in the TACE-non-refractory group (n = 27; 95% CI, 183.5-2,464.5). Conclusions: TACE refractoriness impairs the OS of HCC patients. The number of tumors and bilobular invasion status were independent risk factors for TACE refractoriness. The TACE refractoriness score can be an effective tool and easy approach to predict the risk of TACE refractoriness status.
引用
收藏
页数:9
相关论文
共 35 条
[1]   Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma [J].
Arizumi, Tadaaki ;
Ueshima, Kazuomi ;
Minami, Tomohiro ;
Kono, Masashi ;
Chishina, Hirokazu ;
Takita, Masahiro ;
Kitai, Satoshi ;
Inoue, Tatsuo ;
Yada, Norihisa ;
Hagiwara, Satoru ;
Minami, Yasunori ;
Sakurai, Toshiharu ;
Nishida, Naoshi ;
Kudo, Masatoshi .
LIVER CANCER, 2015, 4 (04) :253-262
[2]   Prognostic prediction and treatment strategy in hepatocellular carcinoma [J].
Bruix, J ;
Llovet, JM .
HEPATOLOGY, 2002, 35 (03) :519-524
[3]   Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel [J].
Cheng, Ann Lii ;
Amarapurkar, Deepak ;
Chao, Yee ;
Chen, Pei-Jer ;
Geschwind, Jean-Francois ;
Goh, Khean L. ;
Han, Kwang-Hyub ;
Kudo, Masatoshi ;
Lee, Han Chu ;
Lee, Rheun-Chuan ;
Lesmana, Laurentius A. ;
Lim, Ho Yeong ;
Paik, Seung Woon ;
Poon, Ronnie T. ;
Tan, Chee-Kiat ;
Tanwandee, Tawesak ;
Teng, Gaojun ;
Park, Joong-Won .
LIVER INTERNATIONAL, 2014, 34 (02) :174-183
[4]  
European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
[5]   Hepatocellular carcinoma [J].
Forner, Alejandro ;
Reig, Maria ;
Bruix, Jordi .
LANCET, 2018, 391 (10127) :1301-1314
[6]   Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects [J].
Forner, Alejandro ;
Reig, Maria E. ;
Rodriguez de Lope, Carlos ;
Bruix, Jordi .
SEMINARS IN LIVER DISEASE, 2010, 30 (01) :61-74
[7]   Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment [J].
Hiraoka, Atsushi ;
Kumagi, Teru ;
Hirooka, Masashi ;
Uehara, Takahide ;
Kurose, Kiyotaka ;
Iuchi, Hidehito ;
Hiasa, Yoichi ;
Matsuura, Bunzo ;
Michitaka, Kojiro ;
Kumano, Seishi ;
Tanaka, Hiroaki ;
Yamashita, Yoshimasa ;
Horiike, Norio ;
Mochizuki, Teruhito ;
Onji, Morikazu .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (13) :2075-2079
[8]   Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization [J].
Hiraoka, Atsushi ;
Ishimaru, Yoshihiro ;
Kawasaki, Hideki ;
Aibiki, Toshihiko ;
Okudaira, Tomonari ;
Toshimori, Akiko ;
Kawamura, Tomoe ;
Yamago, Hiroka ;
Nakahara, Hiromasa ;
Suga, Yoshifumi ;
Azemoto, Nobuaki ;
Miyata, Hideki ;
Miyamoto, Yasunao ;
Ninomiya, Tomoyuki ;
Hirooka, Masashi ;
Abe, Masanori ;
Matsuura, Bunzo ;
Hiasa, Yoichi ;
Michitaka, Kojiro .
ONCOLOGY, 2015, 89 (03) :167-174
[9]   Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization [J].
Ikeda, Masafumi ;
Mitsunaga, Shuichi ;
Shimizu, Satoshi ;
Ohno, Izumi ;
Takahashi, Hideaki ;
Okuyama, Hiroyuki ;
Kuwahara, Akiko ;
Kondo, Shunsuke ;
Morizane, Chigusa ;
Ueno, Hideki ;
Satake, Mitsuo ;
Arai, Yasuaki ;
Okusaka, Takuji .
JOURNAL OF GASTROENTEROLOGY, 2014, 49 (05) :932-940
[10]   Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma [J].
Johnson, Guy E. ;
Monsky, Wayne L. ;
Valji, Karim ;
Hippe, Daniel S. ;
Padia, Siddharth A. .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2016, 27 (08) :1123-1129